Search results for "Coronavirus"


 
Results 91 - 100 of about 166 for "Coronavirus".
Sort by: Relevance | Newest | Oldest

Anaphylaxis appears rare with COVID-19 vaccine, alternative administration strategies considered

The CDC's monitoring system found low rates of anaphylaxis after a first dose of the Pfizer-BioNTech COVID-19 vaccine, peer-reviewed data were published on the Moderna vaccine, and alternate vaccine administration strategies were evaluated.
https://acpinternist.org/weekly/archives/2021/01/12/2.htm
12 Jan 2021

N95 masks and gowns available for purchase through ACP

ACP members can participate in a bulk purchase of N95 masks and gowns, but orders must be received by 3 p.m. ET on Monday, Aug. 24.
https://acpinternist.org/weekly/archives/2020/08/18/2.htm
18 Aug 2020

N95 masks and gowns available from ACP

ACP members can participate in a bulk purchase of N95 masks and gowns, but orders must be received by 3 p.m. on Friday, June 26.
https://acpinternist.org/weekly/archives/2020/06/23/2.htm
23 Jun 2020

New research looks at COVID-19 quarantine length in asymptomatic contacts, convalescent plasma for mild disease, related health issues

Seven-day quarantine may be sufficient for contacts without symptoms, older adults with mild disease may benefit from convalescent plasma, and cardiovascular deaths increased during the early stage of the pandemic.
https://acpinternist.org/weekly/archives/2021/01/12/3.htm
12 Jan 2021

Regulatory changes for COVID-19 vaccine; data on waning immunity, outpatient therapies

The FDA authorized vaccinating children, the NIH supported concurrent use of flu and COVID-19 shots, and the CDC addressed a fourth dose of COVID-19 vaccine for the immunocompromised. Trials found benefit from a new monoclonal antibody and an old antidepressant for high-risk outpatients.
https://acpinternist.org/weekly/archives/2021/11/02/1.htm
2 Nov 2021

Q&A with ACP's President on COVID-19 vaccines

George M. Abraham, MD, MPH, MACP, ACP's President, recently discussed the difference between third shots and boosters and other complexities of vaccination, as well as offered advice to internists on getting more patients vaccinated.
https://acpinternist.org/weekly/archives/2021/11/23/1.htm
23 Nov 2021

Research, regulators consider booster dose of COVID-19 vaccine

FDA advisors recommended boosters for older and high-risk patients. The latest COVID-19 research looked at vaccine effectiveness, remdesivir's effects, an early indicator of vaccine-induced immune thrombotic thrombocytopenia, and rates of follow-up after hospitalization.
https://acpinternist.org/weekly/archives/2021/09/21/1.htm
21 Sep 2021

Studies find monoclonal antibodies and remdesivir effective, while vaccine-associated myocarditis is rare

A trial of casirivimab plus imdevimab indicated it reduced risk of hospitalization or death, the CDC urged vaccination during pregnancy and updated its v-safe tool, and an analysis showed that postvaccine myocarditis occurred in men and resolved with conservative treatment.
https://acpinternist.org/weekly/archives/2021/10/05/1.htm
5 Oct 2021

More data on risk factors for poor COVID-19 outcomes, mixed results from treatment trials

A risk calculator, genetic findings, and red blood cell distribution width helped predict severity of and death from COVID-19. Tocilizumab showed benefit, but a number of other treatments, including CPR, did not, according to recent research.
https://acpinternist.org/weekly/archives/2020/09/29/2.htm
29 Sep 2020

NIH adds another antibody to recommended treatments, studies look at early cases, racial disparities

Recent COVID-19 news includes a new NIH recommendation and studies of the earliest U.S. cases, an experimental inpatient drug, and potential causes of racial disparities in outcomes.
https://acpinternist.org/weekly/archives/2021/06/22/1.htm
22 Jun 2021

Result Page: Prev   5   6   7   8   9   10   11   12   13   14   Next